Probiotic supplementation increases fecal TLR4 agonists without improving disease activity in juvenile idiopathic arthritis: a randomized placebo-controlled trial
VSL#3 for 3 months failed to improve clinical responses in children with juvenile idiopathic arthritis and, under worst-case missing-data assumptions, was associated with lower response rates than placebo.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The PERMAJI trial found no statistically significant difference in ACR Pedi 30 response rates between groups (47% VSL#3 vs 63% placebo; p=0.33). Under conservative worst-case assumptions for missing data, response was significantly lower in the probiotic group (36% vs 68%; p=0.03). Supplementation significantly increased fecal TLR4 agonist activity without changing gut microbiota diversity, intestinal permeability, or systemic cytokines.
How it was done
Multicentre, randomized, double-blind, placebo-controlled trial (1:1) enrolling 44 children with oligoarticular or RF-negative polyarticular JIA, receiving VSL#3 or placebo for 3 months alongside standard therapy. Stool and serum samples at baseline and month 3 assessed microbiota composition, fecal innate immune agonists, intestinal permeability, and cytokines.
Risk of bias
The sample of 44 participants is small, limiting statistical power to detect modest clinical differences. The abstract does not detail dropout rates or the precise distribution of JIA subtypes, hampering assessment of representativeness.
What this study does NOT prove
The study does not prove that probiotics are safe or immunologically neutral in JIA; elevated TLR4 agonists indicate a biological effect whose clinical direction remains unclear.
In clinical practice
Available data do not support VSL#3 as a therapeutic adjunct in pediatric JIA. The observed increase in TLR4 agonist activity warrants caution regarding potential pro-inflammatory signalling.
Limitations
The sample of 44 participants is small, limiting statistical power to detect modest clinical differences. The abstract does not detail dropout rates or the precise distribution of JIA subtypes, hampering assessment of representativeness.
Technical appendix
Version history
- 1.0 · 2026-09-11 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.